secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2021-09-17T23:59:59+00:00
Accession:  0001493152-21-022964
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric completes MagicMed acquisition; issues 9.95M shares (~31.7% ownership)
------------------------------------------------------------------------------

- Enveric issued 9,951,237 shares to MagicMed shareholders, representing ~31.7% of combined company.
- Enveric received ~$4 million CAD cash from MagicMed treasury at closing.
- Dr. Joseph Tucker (ex-MagicMed CEO) appointed CEO of Enveric; David Johnson becomes Executive Chairman.
- Dr. Peter Facchini appointed Chief Scientific Officer; Dr. Jillian Hagel appointed Chief Technology Officer.
- Board expanded from 5 to 7; Tucker and Brad Thompson joined as directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-022964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer